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Background: Maintenance of consistent anticoagulation is a tenet in management of patients with mechanical heart valves. However, 
withdrawal is sometimes necessary due to comorbidities, but no data exist regarding a possible “safe period”. We assessed this in patients 
undergoing neurosurgical procedures in which anticoagulation withdrawal is mandatory.
methods:  Cleveland Clinic main campus databases were matched for patients with mechanical heart prosthesis and who underwent 
cranial or spinal surgery between 3/2004 and 11/2012. This retrospective study examined adults >18 years of age with one or more mitral 
or aortic mechanical valve(s) (excluding implants within 3 months of their surgical procedure and bioprosthesis). The unanticoagulated 
interval was recorded. The primary outcome of thromboembolic events was a composite including: new embolic stroke, ischemic limb, 
and evidence of valvular thrombosis in the perioperative period. Secondary outcome of hemorrhagic complications was determined by a 
standardized bleeding definition.
results:  Of over 30,000 neurosurgical procedures (62% cranial and 35% spinal), 45 patients had mechanical valves. Unanticoagulation 
interval was 12.8 ± 19 days mean of 7daysf, of which 85.7% were on warfarin. 37% of patients did not receive bridging therapy with 
the remaining receiving intravenous heparin or Low molecular weight heparin (LMWH), 28% and 33% respectively. The incidence of 
thromboembolic complication peri-operatively up to a follow up of 3 months was zero. In contrast, 20% of patients developed a major 
hemorrhagic complication after restarting anticoagulation during this same post-operative period. A total of 3 deaths were observed post-
operatively (1 pulmonary embolism; 2 cardiac arrests).
conclusion:  In patients with mechanical heart prosthesis undergoing a neurosurgical procedure, stopping anticoagulation for over 12 days 
failed to trigger any thromboembolic events. Rather, early reinitiation caused significant patient morbidity. The results invert established 
dogma regarding withdrawal and reinititation of anticoagulation in patients with mechanical heart valves.
